Health and Human Services Department, Food and Drug Administration
The Food and Drug Administration (FDA) is announcing the renewal of the Pulmonary-Allergy Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Pulmonary- Allergy Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the May 30, 2028, expiration date.
Document Headings Document headings vary by document type but may contain the following: the agency or agencies that issued and signed a document the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to the agency docket number / agency internal file number the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions See the Document Drafting Handbook for more details. Department of Health and Human Services Food and Drug Administration [Docket No. FDA-2026-N-0008] ( printed page 30654) AGENCY: Food and Drug Administration, HHS. ACTION: Notice; renewal of Federal advisory committee. SUMMARY: The Food and Drug Administration (FDA) is announcing the renewal of the Pulmonary-Allergy Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Pulmonary-Allergy Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the May 30, 2028, expiration date. DATES: Authority for the Pulmonary-Allergy Drugs Advisory Committee will expire on May 30, 2026, unless the Commissioner formally determines that renewal is in the public interest. FOR FURTHER INFORMATION CONTACT: Advisory Committee Oversight and Management Staff, Office of the Chief Scientist, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 1, Rm. 3215, Silver Spring, MD 20993-0002, (301) 796-8220, ACOMSSubmissions@fda.hhs.gov . SUPPLEMENTARY INFORMATION: Pursuant to 41 CFR 102-3.65 and approval by the Department of Health and Human Services and by the General Services Administration, FDA is announcing the renewal of the Pulmonary-Allergy Drugs Advisory Committee (the Committee). The Committee is a discretionary Federal advisory committee established to provide advice to the Commissioner. The Committee advises the …
Other Federal Register documents from the same docket.
Advisory Committee; Psychopharmacologic Drugs Advisory Committee; Renewal
Advisory Committee; Drug Safety and Risk Management Advisory Committee; Renewal
Advisory Committee; Blood Products Advisory Committee; Renewal
Advisory Committee; Pharmacy Compounding Advisory Committee; Renewal
Advisory Committee; Obstetrics, Reproductive and Urologic Drugs Advisory Committee; Renewal
Citation: 91 FR 30654
